|
Gene: CPVL |
Gene summary for CPVL |
Gene summary. |
Gene information | Species | Human | Gene symbol | CPVL | Gene ID | 54504 |
Gene name | carboxypeptidase vitellogenic like | |
Gene Alias | HVLP | |
Cytomap | 7p14.3 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A024RA40 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54504 | CPVL | LZE20T | Human | Esophagus | ESCC | 4.83e-07 | 3.48e-01 | 0.0662 |
54504 | CPVL | LZE22T | Human | Esophagus | ESCC | 1.11e-08 | 5.66e-01 | 0.068 |
54504 | CPVL | LZE24T | Human | Esophagus | ESCC | 1.33e-11 | 2.88e-01 | 0.0596 |
54504 | CPVL | P1T-E | Human | Esophagus | ESCC | 1.06e-02 | 3.56e-01 | 0.0875 |
54504 | CPVL | P2T-E | Human | Esophagus | ESCC | 6.61e-16 | 4.20e-01 | 0.1177 |
54504 | CPVL | P4T-E | Human | Esophagus | ESCC | 6.64e-43 | 1.03e+00 | 0.1323 |
54504 | CPVL | P8T-E | Human | Esophagus | ESCC | 4.87e-29 | 8.80e-01 | 0.0889 |
54504 | CPVL | P10T-E | Human | Esophagus | ESCC | 3.27e-19 | 4.92e-01 | 0.116 |
54504 | CPVL | P11T-E | Human | Esophagus | ESCC | 3.10e-17 | 9.49e-01 | 0.1426 |
54504 | CPVL | P12T-E | Human | Esophagus | ESCC | 1.89e-15 | 3.19e-01 | 0.1122 |
54504 | CPVL | P16T-E | Human | Esophagus | ESCC | 4.73e-50 | 1.09e+00 | 0.1153 |
54504 | CPVL | P20T-E | Human | Esophagus | ESCC | 5.35e-20 | 5.00e-01 | 0.1124 |
54504 | CPVL | P22T-E | Human | Esophagus | ESCC | 1.88e-14 | 1.36e-01 | 0.1236 |
54504 | CPVL | P26T-E | Human | Esophagus | ESCC | 2.54e-30 | 6.27e-01 | 0.1276 |
54504 | CPVL | P27T-E | Human | Esophagus | ESCC | 8.17e-21 | 5.20e-01 | 0.1055 |
54504 | CPVL | P37T-E | Human | Esophagus | ESCC | 9.22e-04 | 1.12e-01 | 0.1371 |
54504 | CPVL | P39T-E | Human | Esophagus | ESCC | 2.09e-07 | 1.15e-01 | 0.0894 |
54504 | CPVL | P52T-E | Human | Esophagus | ESCC | 1.28e-04 | 1.98e-01 | 0.1555 |
54504 | CPVL | P56T-E | Human | Esophagus | ESCC | 4.54e-13 | 1.27e+00 | 0.1613 |
54504 | CPVL | P61T-E | Human | Esophagus | ESCC | 2.87e-24 | 6.91e-01 | 0.099 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CPVL | SNV | Missense_Mutation | novel | c.270C>G | p.Phe90Leu | p.F90L | Q9H3G5 | protein_coding | deleterious(0) | benign(0.305) | TCGA-CR-7364-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CPVL | SNV | Missense_Mutation | novel | c.1366C>G | p.Leu456Val | p.L456V | Q9H3G5 | protein_coding | tolerated(0.23) | benign(0.253) | TCGA-D6-6826-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CPVL | deletion | Frame_Shift_Del | c.794delN | p.Lys265SerfsTer11 | p.K265Sfs*11 | Q9H3G5 | protein_coding | TCGA-CN-4727-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD | |||
CPVL | SNV | Missense_Mutation | rs540733056 | c.742N>A | p.Gly248Ser | p.G248S | Q9H3G5 | protein_coding | tolerated(0.22) | benign(0.393) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CPVL | SNV | Missense_Mutation | rs376043843 | c.962N>T | p.Thr321Met | p.T321M | Q9H3G5 | protein_coding | tolerated(0.06) | benign(0.175) | TCGA-BR-6566-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CPVL | SNV | Missense_Mutation | rs572392082 | c.493N>G | p.Thr165Ala | p.T165A | Q9H3G5 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
CPVL | SNV | Missense_Mutation | rs750931528 | c.406C>T | p.Arg136Cys | p.R136C | Q9H3G5 | protein_coding | tolerated(0.07) | benign(0.011) | TCGA-CG-4306-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CPVL | SNV | Missense_Mutation | c.291A>G | p.Ile97Met | p.I97M | Q9H3G5 | protein_coding | tolerated(0.19) | benign(0.033) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD | |
CPVL | SNV | Missense_Mutation | novel | c.316N>A | p.Leu106Ile | p.L106I | Q9H3G5 | protein_coding | deleterious(0.03) | possibly_damaging(0.858) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
CPVL | deletion | Frame_Shift_Del | c.1251delN | p.Val418PhefsTer24 | p.V418Ffs*24 | Q9H3G5 | protein_coding | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |